Journal article
The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk
Abstract
AIMS: Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The low-dose colchicine 2 (LoDoCo2) trial showed that colchicine reduced the risk of cardiovascular events occurring on standard therapies in patients with chronic coronary syndrome (CCS). We explored the effects of colchicine on Lp(a)- and oxidized lipoprotein-associated risk in a LoDoCo2 biomarker …
Authors
Mohammadnia N; van Broekhoven A; Bax WA; Eikelboom JW; Mosterd A; Fiolet ATL; Tijssen JGP; Thompson PL; de Kleijn DPV; Tsimikas S
Journal
European Journal of Preventive Cardiology, Vol. 32, No. 9, pp. 758–765
Publisher
Oxford University Press (OUP)
Publication Date
July 14, 2025
DOI
10.1093/eurjpc/zwae355
ISSN
2047-4873